MedTrace Logo

"MILNACIPRAN" in Subjects With Chronic Shoulder Pain

NCT01289236 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-08-09

No results posted yet for this study

Summary

The purpose of this study is to compare the safety and efficacy of multiple doses of "Milnacipran" to a placebo dose in subjects with Chronic Shoulder Pain.

Conditions

  • Chronic Shoulder Pain

Interventions

DRUG

milnacipran

1 tablet (50mg) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period

DRUG

Milnacipran

1 tablet (100mg) BID (twice daily, approximately 12 hours apart)for 12 weeks after appropriate titration period.

DRUG

Placebo

1 tablet (placebo) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period.

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • Valera Bussell

    lead INDUSTRY

Principal Investigators

  • Philippe A Saxe, MD,FACP · Delray Research Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01289236 on ClinicalTrials.gov